Abstract: The present disclosure relates to a HLA-G specific chimeric antigen receptor, a nucleic acid, a HLA-G specific chimeric antigen receptor expression plasmid, a HLA-G specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the HLA-G specific chimeric antigen receptor expressing cell. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expression plasmid expresses the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expressing cell is obtained by transducing the HLA-G specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the HLA-G specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

Abstract: The present disclosure provides an engineered stem cell, comprising a vector comprising a polynucleotide comprising a nucleic acid sequence of suicide gene, a nucleic acid sequence of immune checkpoint gene and a natural cytotoxicity triggering receptor or a TNF-related apoptosis-inducing ligand, wherein the stem cell is a tumor-targeting cell. The present disclosure also provides a method for treating a cancer or enhancing intratumor immunity or enhancing immunity in tumor microenvironment in a subject, comprising administering an effective amount of the engineered stem cell of the present disclosure to the subject.

Abstract: An atrial fibrillation prediction system is provided. The atrial fibrillation prediction system includes an electrocardiogram obtaining unit and a non-transitory machine-readable medium. The non-transitory machine-readable medium is configured for storing a program which is executed by a processing unit to obtain a prediction result. The program includes a reference database obtaining module, a reference feature selecting module, a training module, a target feature selecting module and a comparing module.

Abstract: The present disclosure relates to a use of an ADAM9 inhibitor in manufacture of an immunomodulator. The immunomodulator can change the distribution of immune cells in a tumor and increase the infiltration of the immune cells, thereby increasing the efficacy of cancer immunotherapy. Furthermore, the immunomodulator can be used to enhance an effectiveness of a cancer immunotherapy, and the ADAM9 inhibitor can be a compound of Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof.

Abstract: A retrievable puncture anchor includes a fixator with a cylindrical structure, a retrievable thread secured to one end of the fixator, and a push cable flexibly connected to a middle part of the fixator. Via the retrievable puncture anchor, tissues may be connected, fixed and matched with each other, or the tissues may be auxiliarily fixed, so that endoscopic surgery may be facilitated with simplified surgical process, and the puncture anchor may be retrieved after the surgery.

Abstract: The present disclosure relates to an ADAM9 inhibitor compound of formula (I), including salts, hydrates and stereoisomers thereof, compositions thereof, and methods of use therefor, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Abstract: Disclosed is a method for identifying methicillin-resistant Staphylococcus aureus through detection a mass signal at m/z of 6580-6600 in the MALDI-TOF mass spectrum. Also disclosed is a novel peptide biomarker, which consists of SEQ NO ID:5 and the use thereof for detection and/or identification of methicillin-resistant Staphylococcus aureus.

Abstract: A method for analyzing biological-tissue image includes following steps. A plurality of biological-tissue images are provided, and each of the biological-tissue images includes a plurality of target object image blocks. An image pre-processing step is performed so as to obtain a plurality of processed biological-tissue images. A fitting step is performed so as to obtain a plurality of object fitting images of the target object image blocks. A sampling step is performed, wherein a target region of each of the processed biological-tissue images is selected, and the target region includes the object fitting images. A calculating and analyzing step is performed so as to obtain an analysis result of a target regional center of the biological-tissue images.

Abstract: A method for assessing cardiothoracic ratio (CTR) includes following steps. A testing X-ray image database of a subject is provided. A first image data classifying step is performed, wherein the testing X-ray image database is classified by a first deep learning neural network classifier to obtain a testing chest X-ray image data. A second image data classifying step is performed, wherein the testing chest X-ray image data is classified by a second deep learning neural network classifier to obtain a target chest X-ray image data. A feature extracting step is performed, wherein a diameter of thoracic cavity and a diameter of cardiac silhouette of the target chest X-ray image data are captured automatically and then trained to achieve a convergence by a third deep learning neural network classifier. An assessing step is performed, wherein an assessing result of CTR is obtained according to a feature of CTR.

Abstract: A method for assessing acute kidney injury includes following steps. An acute kidney injury assessing date of a subject is provided. A testing kidney function diagnostic dataset is provided, wherein the testing kidney function diagnostic dataset includes a plurality of serum creatinine concentration data and a plurality of glomerular filtration rate data, and a recording date of each of the serum creatinine concentration data and a recording date of each of the glomerular filtration rate data is on 0 to 180 days before the acute kidney injury assessing date. A preprocessing step is performed. A first classifying step is performed, wherein a fluctuation value of serum creatinine concentration is classified according to a first threshold or a fluctuation value of eGFR is classified according to a second threshold so as to obtain a result of AKI status of the subject.

Abstract: Disclosed is a method for identifying methicillin-resistant Staphylococcus aureus through detection a mass signal at m/z of 6580-6600 in the MALDI-TOF mass spectrum. Also disclosed is a novel peptide biomarker, which consists of SEQ NO ID:5 and the use thereof for detection and/or identification of methicillin-resistant Staphylococcus aureus.

Abstract: The invention relates to method of diagnosis a subject suffering from Adult-onset Still's disease and further to determine the disease course of the subject suffering from Adult-onset Still's disease.

Abstract: The present disclosure relates to a method for inhibiting a binding of a SARS-CoV-2 spike protein of a SARS-CoV-2 to an angiotensin-converting enzyme 2 including contacting the SARS-CoV-2 with a sufficient concentration of disulfiram, a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of disulfiram, and a method for inhibiting an activity of a papain-like protease (PLpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of disulfiram. A method for inhibiting a replication or an infection of a SARS-CoV-2 in a cell includes contacting the cell with a sufficient concentration of disulfiram and a medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of disulfiram are also provided.

Abstract: The present invention relates to a peptide capable of binding to rheumatoid arthritis autoantibodies, which is a consecutive 10-25 amino acid sequence of any one fragment of the group consisting of SEQ ID NO: 3-4, 7-13 or 16-19, wherein the peptide fragment has an epitope that binds to the rheumatoid arthritis autoantibodies. Furthermore, the peptide fragment bound to the rheumatoid arthritis autoantibodies is used for testing rheumatoid arthritis, and according to this use, the present invention provides a method for testing rheumatoid arthritis disease and a test reagent kit used for determining whether a subject to be tested suffers from rheumatoid arthritis disease.

Abstract: A computer-aided recognition system for treatment response of rectal cancer is provided to predict the probability of a pathological complete response (pCR) of a rectal cancer patient after preoperative neoadjuvant chemoradiotherapy. The system includes a random forest model having several decision trees. Each decision tree has at least a feature node. Each feature node generates two branches according to a feature threshold, wherein each branch connects to another feature node or corresponds to an elementary pCR predicting probability. The random forest model integrates the elementary pCR probability of each decision tree, so as to generate a final pCR probability.

Abstract: The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir. A medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir is also provided.

Abstract: The present invention relates to a biomarker and target for diagnosis, prognosis and treatment of ankylosing spondylitis (AS). The present invention also relates to a method for producing an animal model for AS, an animal model produced therefrom, and a method for screening for an agent pharmaceutically active in the treatment of A S using such animal model.

Abstract: The present invention provides a pharmaceutical composition for treating and/or relieving myopia, the pharmaceutical composition comprises a therapeutically effective amount of an anti-inflammatory agent and a pharmaceutically acceptable carrier; the pharmaceutical composition of the present invention is safe, and can treat and/or relieve myopia by the anti-inflammatory agent. The pharmaceutically acceptable carrier can effectively encapsulate the anti-inflammatory agent at a specific ratio, and the stability and solubility of the pharmaceutical composition can be enhanced.

Abstract: The invention provides a novel class of propiolylamide-based irreversible inhibitors of PKM2 compounds of the general formula I, pharmaceutical compositions, and methods of inducing an anti-tumor effect in a subject suffering from tumor comprising administering to the subject a pharmaceutical composition comprising an effective amount of compound of formula I.

Abstract: A method for treating a multiple sclerosis is provided. The method includes administering a composition containing a plurality of mesenchymal stem cells to a subject in need for a treatment of the multiple sclerosis, in which each of the mesenchymal stem cells expresses insulin-like growth factor 1 receptors.